deltatrials
Completed PHASE2 INTERVENTIONAL 2-arm NCT02422966

Paracetamol in Patent Ductus Arteriosus

Efficacy and Safety of Paracetamol in Comparison to Ibuprofen for Patent Ductus Arteriosus Treatment in Preterm Infants: A Randomized, Open Label, Comparator-controlled, Prospective Study

Sponsor: Aziende Chimiche Riunite Angelini Francesco S.p.A

Updated 8 times since 2017 Last updated: Jul 11, 2019 Started: Dec 31, 2015 Primary completion: Jan 31, 2019 Completion: Apr 30, 2019
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Ductus Arteriosus, Patent, this trial is completed. The trial is conducted by Aziende Chimiche Riunite Angelini Francesco S.p.A and has accumulated 8 data snapshots since 2015. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Jan 2017 – ~Jun 2018 · 17 months · monthly snapshotRecruiting~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshotRecruiting~Jul 2018 – ~Aug 2019 · 13 months · monthly snapshotRecruiting~Aug 2019 – ~Jan 2021 · 17 months · monthly snapshotCompleted~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshotCompleted~Sep 2025 – present · 10 months · monthly snapshotCompleted

Change History

8 versions recorded
  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  5. Aug 2019 — Jan 2021 [monthly]

    Completed PHASE2

    Status: RecruitingCompleted

Show 3 earlier versions
  1. Jul 2018 — Aug 2019 [monthly]

    Recruiting PHASE2

  2. Jun 2018 — Jul 2018 [monthly]

    Recruiting PHASE2

  3. Jan 2017 — Jun 2018 [monthly]

    Recruiting PHASE2

    First recorded

Dec 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Aziende Chimiche Riunite Angelini Francesco S.p.A
Data source: Aziende Chimiche Riunite Angelini Francesco S.p.A

For direct contact, visit the study record on ClinicalTrials.gov .